<ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>Kymera Therapeutics, Inc. (NASDAQ:KYMR - 免费报告) - Leerink Partners 的投资分析师在 8 月 11 日星期一向投资者发布了对 Kymera Therapeutics 第三季度 2026 年的收益预期。Leerink Partners 分析师 F. Khurshid 预计该公司本季度每股收益为（$1.09）。Kymera Therapeutics 当前全年的共识收益预期为每股（$2.79）。Leerink Partners 还发布了对 Kymera Therapeutics 第四季度 2026 年收益的预期为每股（$1.11）。</p>
<p>其他一些券商最近也对 KYMR 发表了评论。Oppenheimer 在 6 月 27 日星期五的研究报告中重申了 “跑赢大盘” 的评级，并将 Kymera Therapeutics 的目标价下调至 $53.00（之前为 $56.00）。Jefferies Financial Group 在 6 月 25 日星期三的研究报告中对 Kymera Therapeutics 的股票设定了 $64.00 的目标价，并给予该股票 “买入” 评级。高盛集团在 7 月 15 日星期二的研究报告中将 Kymera Therapeutics 的股票评级提升至 “强力买入”。摩根士丹利在 7 月 3 日星期四的研究报告中开始覆盖 Kymera Therapeutics 的股票。他们为该公司设定了 “增持” 评级和 $70.00 的目标价。最后，富国银行在 6 月 26 日星期四的研究报告中将 Kymera Therapeutics 的目标价从 $57.00 下调至 $53.00，并为该公司设定了 “增持” 评级。两位投资分析师对该股票给予了持有评级，十六位给予了买入评级，三位给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 $59.11。</p>
<p>获取 <strong>Kymera Therapeutics</strong> 的提醒：</p>
<p><strong>获取我们对 Kymera Therapeutics 的最新股票分析</strong></p>
<h2>Kymera Therapeutics 股票上涨 5.4%</h2>
<p>NASDAQ:KYMR 的股票在星期三开盘价为 $39.71。Kymera Therapeutics 的 52 周低点为 $19.44，52 周高点为 $53.27。该股票的市值为 $25.9 亿，市盈率为 -11.54，贝塔值为 2.18。该公司的 50 日简单移动平均线为 $44.93，200 日简单移动平均线为 $36.45。</p>
<p>Kymera Therapeutics (NASDAQ:KYMR - 获取免费报告) 最近在 8 月 11 日星期一宣布了其季度收益结果。该公司报告本季度每股收益为（$0.95），低于分析师的共识预期（$0.83）$0.12。该公司在本季度的收入为 $1148 万，而共识预期为 $1737 万。Kymera Therapeutics 的净利润率为 -616.03%，股本回报率为 -32.86%。该公司的收入同比下降了 55.1%。在去年同期，该公司每股收益为（$0.58）。</p>
<h2>Kymera Therapeutics 的内部买卖</h2>
<p>在其他 Kymera Therapeutics 的新闻中，董事 Jeffrey W. Albers 在 6 月 3 日星期二出售了 6,349 股公司的股票。股票以平均价格 $49.00 出售，总交易额为 $311,101.00。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，董事 Bvf Partners L. P/Il 在 6 月 30 日星期一购买了 317,167 股公司的股票。股票以每股平均价格 $44.00 购买，总交易额为 $13,955,348.00。购买后，该董事直接持有公司 2,798,795 股，价值 $123,146,980。这代表其持股比例增加了 12.78%。该购买的披露信息可以在这里找到。在过去三个月中，内部人士共出售了价值 $2,334,301 的 48,349 股公司股票。公司内部人士持有该股票的 16.01%。</p>
<h2>机构资金流入和流出</h2>
<p>对该股票的对冲基金最近进行了买卖。Franklin Resources Inc. 在第四季度将其在 Kymera Therapeutics 的股份增加了 30.3%。Franklin Resources Inc. 目前拥有 38,367 股公司股票，价值 $1,544,000，此前在该期间内又增持了 8,927 股。Geode Capital Management LLC 在第四季度将其在 Kymera Therapeutics 的股份增加了 5.0%。Geode Capital Management LLC 目前拥有 1,105,487 股公司股票，价值 $44,484,000，此前在该期间内又增持了 52,263 股。富国银行 MN 在第四季度将其在 Kymera Therapeutics 的股份增加了 51.8%。富国银行 MN 目前拥有 21,939 股公司股票，价值 $883,000，此前在该期间内又增持了 7,487 股。Summit Investment Advisors Inc. 在第四季度将其在 Kymera Therapeutics 的股份增加了 9.0%。Summit Investment Advisors Inc. 目前拥有 4,912 股公司股票，价值 $198,000，此前在该期间内又增持了 406 股。最后，Affinity Asset Advisors LLC 在第四季度获得了 Kymera Therapeutics 的新股份，价值 $1,609,000。</p>
<h2>Kymera Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Kymera Therapeutics, Inc. 是一家生物制药公司，专注于发现和开发新型小分子治疗药物，通过利用身体自身的自然蛋白质降解系统选择性降解致病蛋白。它正在开发 IRAK4 项目，该项目正在进行 II 期临床试验，治疗免疫学 - 炎症疾病，包括脓疱性汗腺炎、特应性皮炎；STAT3 项目用于治疗血液恶性肿瘤和实体肿瘤，以及自身免疫疾病和纤维化；MDM2 项目用于治疗血液恶性肿瘤和实体肿瘤。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Kymera Therapeutics</li>
<li>如何开始投资房地产</li>
<li>数据中心需求旺盛——这只 REIT 拥有整个投资组合</li>
<li>股票平均计算器</li>
<li>3 只电池股票，适合买入并持有到本十年结束</li>
<li>日经 225 指数是什么？</li>
<li>在能源市场紧张局势加剧时值得考虑的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Kymera Therapeutics 吗？</h2>
<p>在考虑 Kymera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Kymera Therapeutics 并不在名单上。</p>
<p>虽然 Kymera Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KYMR

<p>Leerink Partners 的投资分析师发布了 Kymera Therapeutics 2026 年第三季度的收益预估，预测每股收益为（$1.09）。全年共识为每股（$2.79）。其他券商提供了不同的评级和价格目标，平均目标价为$59.11。Kymera 的股票上涨了 5.4%，目前价格为$39.71，市值为 25.9 亿美元。该公司报告上个季度每股收益亏损（$0.95），未达到预期，收入同比下降了 55.1%</p>

<ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2026 earnings estimates for shares of Kymera Therapeutics in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($1.09) for the quarter. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.11) EPS.</p>
<div class="lb-trans"><p>Kymera Therapeutics, Inc. (NASDAQ:KYMR - 免费报告) - Leerink Partners 的投资分析师在 8 月 11 日星期一向投资者发布了对 Kymera Therapeutics 第三季度 2026 年的收益预期。Leerink Partners 分析师 F. Khurshid 预计该公司本季度每股收益为（$1.09）。Kymera Therapeutics 当前全年的共识收益预期为每股（$2.79）。Leerink Partners 还发布了对 Kymera Therapeutics 第四季度 2026 年收益的预期为每股（$1.11）。</p>
</div><p>A number of other brokerages have also recently commented on KYMR. Oppenheimer reissued an &#34;outperform&#34; rating and issued a $53.00 price objective (down from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, June 25th. The Goldman Sachs Group raised shares of Kymera Therapeutics to a &#34;strong-buy&#34; rating in a research note on Tuesday, July 15th. Morgan Stanley initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 3rd. They set an &#34;overweight&#34; rating and a $70.00 price target for the company. Finally, Wells Fargo &amp; Company dropped their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, June 26th. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $59.11.</p>
<div class="lb-trans"><p>其他一些券商最近也对 KYMR 发表了评论。Oppenheimer 在 6 月 27 日星期五的研究报告中重申了 “跑赢大盘” 的评级，并将 Kymera Therapeutics 的目标价下调至 $53.00（之前为 $56.00）。Jefferies Financial Group 在 6 月 25 日星期三的研究报告中对 Kymera Therapeutics 的股票设定了 $64.00 的目标价，并给予该股票 “买入” 评级。高盛集团在 7 月 15 日星期二的研究报告中将 Kymera Therapeutics 的股票评级提升至 “强力买入”。摩根士丹利在 7 月 3 日星期四的研究报告中开始覆盖 Kymera Therapeutics 的股票。他们为该公司设定了 “增持” 评级和 $70.00 的目标价。最后，富国银行在 6 月 26 日星期四的研究报告中将 Kymera Therapeutics 的目标价从 $57.00 下调至 $53.00，并为该公司设定了 “增持” 评级。两位投资分析师对该股票给予了持有评级，十六位给予了买入评级，三位给予了强力买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 $59.11。</p>
</div><p>Get <strong>Kymera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kymera Therapeutics</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Stock Analysis on Kymera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Kymera Therapeutics 的最新股票分析</strong></p>
</div><h2>Kymera Therapeutics Stock Up 5.4%</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 股票上涨 5.4%</h2>
</div><p>Shares of NASDAQ:KYMR opened at $39.71 on Wednesday. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $53.27. The stock has a market capitalization of $2.59 billion, a P/E ratio of -11.54 and a beta of 2.18. The firm has a fifty day simple moving average of $44.93 and a two-hundred day simple moving average of $36.45.</p>
<div class="lb-trans"><p>NASDAQ:KYMR 的股票在星期三开盘价为 $39.71。Kymera Therapeutics 的 52 周低点为 $19.44，52 周高点为 $53.27。该股票的市值为 $25.9 亿，市盈率为 -11.54，贝塔值为 2.18。该公司的 50 日简单移动平均线为 $44.93，200 日简单移动平均线为 $36.45。</p>
</div><p>Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 32.86%. The business's revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.58) earnings per share.</p>
<div class="lb-trans"><p>Kymera Therapeutics (NASDAQ:KYMR - 获取免费报告) 最近在 8 月 11 日星期一宣布了其季度收益结果。该公司报告本季度每股收益为（$0.95），低于分析师的共识预期（$0.83）$0.12。该公司在本季度的收入为 $1148 万，而共识预期为 $1737 万。Kymera Therapeutics 的净利润率为 -616.03%，股本回报率为 -32.86%。该公司的收入同比下降了 55.1%。在去年同期，该公司每股收益为（$0.58）。</p>
</div><h2>Insider Buying and Selling at Kymera Therapeutics</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 的内部买卖</h2>
</div><p>In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bvf Partners L. P/Il purchased 317,167 shares of the business's stock in a transaction on Monday, June 30th. The shares were bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. This represents a 12.78% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 in the last three months. 16.01% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Kymera Therapeutics 的新闻中，董事 Jeffrey W. Albers 在 6 月 3 日星期二出售了 6,349 股公司的股票。股票以平均价格 $49.00 出售，总交易额为 $311,101.00。该交易在向 SEC 提交的文件中披露，文件可在此链接查看。此外，董事 Bvf Partners L. P/Il 在 6 月 30 日星期一购买了 317,167 股公司的股票。股票以每股平均价格 $44.00 购买，总交易额为 $13,955,348.00。购买后，该董事直接持有公司 2,798,795 股，价值 $123,146,980。这代表其持股比例增加了 12.78%。该购买的披露信息可以在这里找到。在过去三个月中，内部人士共出售了价值 $2,334,301 的 48,349 股公司股票。公司内部人士持有该股票的 16.01%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. increased its stake in shares of Kymera Therapeutics by 30.3% in the fourth quarter. Franklin Resources Inc. now owns 38,367 shares of the company's stock worth $1,544,000 after acquiring an additional 8,927 shares during the period. Geode Capital Management LLC increased its stake in shares of Kymera Therapeutics by 5.0% in the fourth quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after acquiring an additional 52,263 shares during the period. Wells Fargo &amp; Company MN increased its stake in shares of Kymera Therapeutics by 51.8% in the fourth quarter. Wells Fargo &amp; Company MN now owns 21,939 shares of the company's stock worth $883,000 after acquiring an additional 7,487 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Kymera Therapeutics in the fourth quarter worth $1,609,000.</p>
<div class="lb-trans"><p>对该股票的对冲基金最近进行了买卖。Franklin Resources Inc. 在第四季度将其在 Kymera Therapeutics 的股份增加了 30.3%。Franklin Resources Inc. 目前拥有 38,367 股公司股票，价值 $1,544,000，此前在该期间内又增持了 8,927 股。Geode Capital Management LLC 在第四季度将其在 Kymera Therapeutics 的股份增加了 5.0%。Geode Capital Management LLC 目前拥有 1,105,487 股公司股票，价值 $44,484,000，此前在该期间内又增持了 52,263 股。富国银行 MN 在第四季度将其在 Kymera Therapeutics 的股份增加了 51.8%。富国银行 MN 目前拥有 21,939 股公司股票，价值 $883,000，此前在该期间内又增持了 7,487 股。Summit Investment Advisors Inc. 在第四季度将其在 Kymera Therapeutics 的股份增加了 9.0%。Summit Investment Advisors Inc. 目前拥有 4,912 股公司股票，价值 $198,000，此前在该期间内又增持了 406 股。最后，Affinity Asset Advisors LLC 在第四季度获得了 Kymera Therapeutics 的新股份，价值 $1,609,000。</p>
</div><h2>Kymera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.</p>
<div class="lb-trans"><p>Kymera Therapeutics, Inc. 是一家生物制药公司，专注于发现和开发新型小分子治疗药物，通过利用身体自身的自然蛋白质降解系统选择性降解致病蛋白。它正在开发 IRAK4 项目，该项目正在进行 II 期临床试验，治疗免疫学 - 炎症疾病，包括脓疱性汗腺炎、特应性皮炎；STAT3 项目用于治疗血液恶性肿瘤和实体肿瘤，以及自身免疫疾病和纤维化；MDM2 项目用于治疗血液恶性肿瘤和实体肿瘤。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Kymera Therapeutics</li>
<li>How to Start Investing in Real Estate</li>
<li>Data Centers in Demand—This REIT Owns a Whole Portfolio</li>
<li>Stock Average Calculator</li>
<li>3 Battery Stocks to Buy and Hold for the Rest of the Decade</li>
<li>What is the Nikkei 225 index?</li>
<li>3 Stocks to Consider as Tension Builds in Energy Markets</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Kymera Therapeutics</li>
<li>如何开始投资房地产</li>
<li>数据中心需求旺盛——这只 REIT 拥有整个投资组合</li>
<li>股票平均计算器</li>
<li>3 只电池股票，适合买入并持有到本十年结束</li>
<li>日经 225 指数是什么？</li>
<li>在能源市场紧张局势加剧时值得考虑的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=KYMR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Kymera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kymera Therapeutics 吗？</h2>
</div><p>Before you consider Kymera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kymera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Kymera Therapeutics 并不在名单上。</p>
</div><p>While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kymera Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Leerink Partners 对 Kymera Therapeutics 第三季度收益的预估是什么？